Skip to content
Sign in

CHRS · NASDAQ

Coherus Oncology (CHRS) Stock Price & Fundamentals

$229.28+0.95%+$2.15End-of-day price as of Oct 9, 2026

Coherus Oncology (CHRS) closed at $229.28 on Oct 9, 2026, up 0.95% from the previous close of $227.13.

Share price, past year

1Y +9.68%

52-week range $195.31 – $235.46. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$229.28
Sep 30, 2026$230.95
Aug 31, 2026$226.49
Jul 31, 2026$230.09
Jun 30, 2026$226.17
May 29, 2026$204.81
Apr 30, 2026$207.83
Mar 31, 2026$217.67
Feb 27, 2026$217.23
Jan 30, 2026$220.56
Dec 31, 2025$212.23
Nov 28, 2025$206.58
Oct 31, 2025$206.93

Key statistics

Market cap
$35.42B
P/E (TTM)
—
EPS (TTM)
−$4.12
Revenue (TTM)
$50.94M
Net income (TTM)
−$132.13M
Shares outstanding
154.5M
Dividend yield
—
52-week range
$195.31 – $235.46

Coherus Oncology's market cap is $35.42B, based on a share price of $229.28 and 154.5M shares outstanding as of Jun 30, 2026.

Financials

Coherus Oncology reported revenue of $42.17M for fiscal 2025, up 59.81% from fiscal 2024.

Coherus Oncology earned net income of $168.02M in fiscal 2025, a net margin of 398.4%.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Coherus Oncology annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$42.17M+59.8%$168.02M398.4%$1.43—
FY2024ended Dec 31, 2024$26.39M−89.7%$28.51M108.0%$0.25—
FY2023ended Dec 31, 2023$257.24M+21.9%−$237.89M−92.5%−$2.53−$175.17M
FY2022ended Dec 31, 2022$211.04M−35.4%−$291.75M−138.2%−$3.76−$243.16M
FY2021ended Dec 31, 2021$326.55M−31.4%−$287.10M−87.9%−$3.81−$38.72M
FY2020ended Dec 31, 2020$475.82M+33.6%$132.24M27.8%$1.62$146.91M
FY2019ended Dec 31, 2019$356.07M—$89.83M25.2%$1.23$26.53M
FY2018ended Dec 31, 2018$0.00−100.0%−$209.34M—−$3.22−$160.06M
FY2017ended Dec 31, 2017$1.56M−99.2%−$238.17M−15,306.6%−$4.48−$204.86M
FY2016ended Dec 31, 2016$190.11M—−$127.34M−67.0%−$3.04−$259.06M
Coherus Oncology quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$14.31M−$20.63M−$0.13
Q1 FY2026ended Mar 31, 2026$12.31M−$38.33M−$0.28
Q4 FY2025ended Dec 31, 2025$12.75M−$37.64M−$3.40
Q3 FY2025ended Sep 30, 2025$11.57M−$35.53M−$0.31
Q2 FY2025ended Jun 30, 2025$10.25M$297.77M$2.57
Q1 FY2025ended Mar 31, 2025$7.60M−$56.57M$2.57
Q4 FY2024ended Dec 31, 2024$7.73M−$50.70M−$0.46
Q3 FY2024ended Sep 30, 2024$6.05M−$10.75M−$0.09

Company profile

Name
Coherus Oncology, Inc.
Ticker
CHRS
Exchange
NASDAQ
Industry (SEC SIC)
Biological Products, (No Diagnostic Substances)
Headquarters
C/O Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600, Redwood City, CA 94065
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001512762

Recent SEC filings

Frequently asked questions

What is Coherus Oncology's stock price?

Coherus Oncology (CHRS) closed at $229.28 on Oct 9, 2026, up 0.95% from the previous close of $227.13.

What is Coherus Oncology's market cap?

Coherus Oncology's market cap is $35.42B, based on a share price of $229.28 and 154.5M shares outstanding as of Jun 30, 2026.

How much revenue does Coherus Oncology make?

Coherus Oncology reported revenue of $42.17M for fiscal 2025, up 59.81% from fiscal 2024.

Does Coherus Oncology pay a dividend?

Coherus Oncology's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Coherus Oncology, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures